The Motley Fool

Why these All Ords shares have doubled in value in 12 months

Over the last 12 months there have been some outstanding performers on the Australian share market.

Some shares have beaten the market with solid gains and others have absolutely smashed it with mouth-watering gains.

Here’s why these All Ordinaries shares have more than doubled in value over the last 12 months:

Codan Limited (ASX: CDA) 

The Codan share price is up an impressive 133% over the last 12 months. Investors have been buying the electronic products manufacturer’s shares thanks to its strong performance in FY 2019 and its very positive start to FY 2020. In respect to the latter, during the first half of FY 2020, Codan delivered revenue of $171 million and EBITDA of $54 million. This was a 33% and 42% increase, respectively on the prior corresponding period. This strong performance has been driven largely by increasing metal detector sales due to a rise in the gold price.

Megaport Ltd (ASX: MP1)

The Megaport share price has been one of the best performers on the market over the last 12 months with a gain of 143%. Investors have been buying the shares of the leading provider of elastic interconnection services due to its impressive growth. Pleasingly, this has continued in FY 2020, with the company recently releasing its half year results for the six months ended December 31. Megaport reported revenue of $25.9 million, which was an increase of 70% on the prior corresponding period. Also growing strongly was its total Monthly Recurring Revenue (MRR), which climbed to $4.6 million at the end of December. This was an increase of $1.9 million or 68% from a year earlier. Finally, Megaport generated a profit after direct network costs of $13.2 million for the half year, which was an increase of $8.3 million or 173%.

Paradigm Biopharmaceuticals Ltd (ASX: PAR)

The Paradigm Biopharmaceuticals share price has been a very positive performer over the last 12 months with a gain of 125%. The catalyst for this was excitement over the biopharmaceutical company’s promising ZILOSUL product. ZILOSUL is the brand name of its repurposing of Pentosan Polysulfate Sodium (PPS). This is an FDA-approved drug that has been used safely for treating inflammation for over 60 years. The company is repurposing PPS to treat osteoarthritis (OA), which is a very lucrative market. Management estimates it could be worth as much as US$27.9 billion per annum in the United States.

NEW. The Motley Fool AU Releases Five Cheap and Good Stocks to Buy for 2020 and beyond!….

Our experts here at The Motley Fool Australia have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.

One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

Another is a diversified conglomerate trading over 40% off its high, all while offering a fully franked dividend yield over 3%...

Plus 3 more cheap bets that could position you to profit over the next 12 months!

See for yourself now. Simply click here or the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.


James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of MEGAPORT FPO. The Motley Fool Australia has recommended MEGAPORT FPO. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.